<DOC>
	<DOCNO>NCT00211003</DOCNO>
	<brief_summary>The purpose study compare safety effectiveness doripenem patient hospital-acquired pneumonia ( HAP ) .</brief_summary>
	<brief_title>Doripenem Treatment Hospital-Acquired Pneumonia</brief_title>
	<detailed_description>Doripenem antibiotic medication yet approve US FDA . This phase 3 , multicenter , prospective , open-label ( though blind outcome assessment ) , randomize study doripenem versus comparator antibiotic patient hospital-acquired pneumonia . The study consist screen phase , open-label treatment phase , follow-up . Both patient ventilator ventilator enrol . The primary endpoint clinical response rate early follow-up visit . The patient may receive either doripenem comparator ; total duration treatment 7 14 day .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<criteria>Patients hospitalize &gt; = 48 hour prior hospital admission least 48 hour discharge within last 48 hour . Hospitalacquired pneumonia know time enrollment cause pathogen ( ) resistant certain antibiotic Any rapidly progressing disease immediately lifethreatening illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Hospital-Acquired Pneumonia</keyword>
	<keyword>Mechanical Ventilation</keyword>
</DOC>